ArticleFrontiers in endocrinology2026
Chaihu-Wendan Decoction alleviates obesity through PTEN-mediated uncoupling of metabolic signaling and macrophage activation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Obesity is increasingly recognized as an immunometabolic disorder driven by dysregulated crosstalk between visceral adipose tissue and the liver, particularly along the liver-omentum axis, which promotes insulin resistance and hepatic steatosis. Although Chaihu-Wendan Decoction (CHWD) is effective for metabolic disorders, its molecular mechanisms of action on this inflammatory axis remains unclear. This study aimed to investigate the therapeutic mechanisms of CHWD in high-fat diet (HFD)-induced obesity model, specifically focusing on insulin signaling and immune microenvironment remodeling in the liver-omentum axis. Method: C57BL/6J mice were fed a HFD to induce obesity and treated with CHWD. Metabolic phenotypes were assessed via biochemical and histological analyses. The molecular mechanisms were explored by evaluating the PTEN/PI3K/AKT/mTOR pathway and omental macrophage profiles using Western blot, ELISA, and immunohistochemistry. Results: CHWD treatment significantly ameliorated HFD-induced body weight gain, dyslipidemia, and hepatic steatosis. Mechanistically, CHWD acted as a regulator of PTEN-associated signaling, which triggered a dual-regulation of PTEN/AKT/mTOR signaling, i.e., robust reactivation of upstream insulin signaling (INSR/IRS1/PI3K/AKT) coupled with the paradoxical suppression of downstream mTOR phosphorylation. This "uncoupling" process restored insulin sensitivity without promoting lipogenesis. Concurrently, CHWD remodeled the omental immune microenvironment by restoring omentin-1 secretion and promoting macrophage phenotype switching, characterized by maintenance of a CD68 Conclusion: CHWD alleviates HFD-induced obesity and metabolic inflammation by coordinately targeting the PTEN/AKT/mTOR axis and reprogramming omental immunity. These findings provide the primary evidence supporting that CHWD modulates the liver-omentum axis via distinct signaling and immune mechanisms, offering a novel therapeutic strategy for metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.